Tradewind BioScience is a biotechnology startup dedicated to developing innovative therapeutics for aggressive cancers. The company's lead program involves a high-affinity, multifaceted attack antibody that inhibits a validated target protein, demonstrating efficacy in in vivo studies. Tradewind's focus on biomarker identification ensures that their therapeutics will significantly benefit patients with the most meaningful impact, with an initial focus on ovarian cancer. Established in 2017 and based in the United States, Tradewind has received a $120.00K Seed Round investment from Y Combinator in January 2018. With backing from Y Combinator and the National Cancer Institute (NCI), Tradewind seeks to revolutionize cancer treatment with its groundbreaking approach.
Tradewind BioScience
Innovative therapeutics for the most aggressive cancers
United States
5 employees
Seed
Total: $120.00K
Biotechnology, Health Care
General Information
United States
BounceWatch is an independent company data service, not affiliated with Tradewind BioScience. To contact Tradewind BioScience, visit tradewindbio.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Tradewind BioScience compare?
A PDF of Tradewind BioScience and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Tradewind BioScience soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
United States Market
Biotechnology
About Tradewind BioScience
Business keywords: therapeutics, antibody, cancer treatment, oncology, innovative medicine, drug development, biomarker identification, ovarian cancer, metastasis, immune system, Y Combinator, National Cancer Institute, game-changer, multifaceted attack
Funding Rounds & Investors (1)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Seed Round | $120.00K | 1 |
|
04 Jan 2018 |
Tradewind BioScience Alternatives & Competitors
View All Alternatives
Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic
Novel Therapeutics for Immunological Diseases
New therapies for inflammatory disease and cancer by targeting fibroblast immunology
FAQ About Tradewind BioScience
Source: BounceWatch company record for Tradewind BioScience, https://bouncewatch.com/company/tradewind-bioscience, updated 21 October 2024. When citing, please name BounceWatch and link this page.
